Blocknomi
Key Highlights TEM shares climbed approximately 24% following encouraging Phase 3 trial results from Merck and Moderna’s cancer vaccine collaboration The positive clinical data enhanced the strategic value of Tempus…
Related articles
-
Solana Investor Appetite Drives 78% Share of Pre-IPO Tokens
BeInCrypto Published 04.08.2026 09:12
-
US, UK reaffirm support for stablecoins, tokenization in joint financial regulation talks
Cointelegraph Published 04.08.2026 19:58
-
Avalanche (AVAX) Price: Holds Near $6.35 as Tokenized Fund Launches
Blocknomi Published 19.08.2026 09:48
-
This Bitcoin Bridge Shut Itself Down Because AI Was Finding Bugs Too Fast
Decrypt Published 04.08.2026 22:46
-
OCC Signals Open Door for National Bank Charters for Digital Asset Firms
BlockchainReporter Published 12.08.2026 13:00
-
Air Canada (AC) Stock Surges 6% Following $2B Blackstone Deal for Aeroplan Stake
Blocknomi Published 12.08.2026 14:26
-
Billionaire Cuban Predicts 'New Crypto'
U.Today Published 16.08.2026 07:55
-
Equity Perp Volume Surges 17x as Chip Stocks Draw Crypto Traders
BeInCrypto Published 14.08.2026 06:54